Skip to Content

Bonnie S. Glisson, M.D.

Present Title & Affiliation

Primary Appointment

Professor of Medicine & Internist, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Chair, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Bonnie S. Glisson, MD is a professor at The University of Texas MD Anderson Cancer Center. Dr Glisson graduated from Ohio State University magna cum laude with a BS and an MD. She was a resident at the University of Virginia and a fellow at the University of Florida. She is board certified in internal medicine and medical oncology.

Dr Glisson holds an Ashbel Smith Professorship in the University of Texas System and has received numerous honors and awards for education and mentoring. She has been listed numerous times in the “The Best Doctors in America” and “America’s Top Doctors”. She is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the American Head and Neck Society. Dr Glisson has given numerous lectures and has published dozens of articles and abstracts.

Office Address

The University of Texas MD Anderson Cancer Center
1400 Holcombe Blvd.
John Mendelsohn Faculty Center Building
Unit Number: 432
Houston, TX 77030
Room Number: FC9.2026
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1979 Ohio State University, Columbus, OH, MD, Medicine
1976 Ohio State University, Columbus, OH, Graduate School, Graduate School
1975 Ohio State University, Columbus, OH, BS, Magna cum laude, Human Nutrition
1971 Central-Hower High School, Akron, OH, High School Diploma, (Class Valedictorian)

Postgraduate Training

1983-1985 Research Fellowship, Pharmacology and Medical Oncology, University of Florida, Gainesville, FL
1982-1983 Clinical Fellowship, Hematology and Medical Oncology, University of Florida, Gainesville, FL
1979-1982 Clinical Residency, Internal Medicine, University of Virginia, Charlottesville, VA


Administrative Appointments/Responsibilities

Department Chair ad interim, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2012-4/2013
Deputy Department Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2010-4/2012

Selected Publications

Peer-Reviewed Original Research Articles

1. Stewart DJ, Johnson C, Lopez A, Glisson B, Rhee JM, Bekele BN. Extensive disease small cell lung cancer dose-response relationships: Implications for resistance mechanisms. J Thorac Oncol 5(11):1826-34, 11/2010. PMCID: PMC2966343.
2. Glisson BS. Targeting an autocrine loop in small-cell lung cancer: irrelevant target or ineffective drug? Clin Lung Cancer 11(4):222, 7/2010. PMID: 20630822.
3. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer as Frontline and Second-Line Therapy. Am J Clin Oncol 33(2):148-52, 4/2010. e-Pub 8/2009. PMID: 19687727.
4. Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, Glisson BS, Chao KS, Schwartz DL, Chronowski GM, El-Naggar AK, Garden AS. Intensity-Modulated Radiotherapy for Cervical Node Squamous Cell Carcinoma Metastases from Unknown Head-and-Neck Primary Site: M. D. Anderson Cancer Center Outcomes and Patterns of Failure. Int J Radiat Oncol Biol Phys. e-Pub 3/2010. PMID: 20207504.
5. Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou V. Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. J Clin Oncol 28(1):8-14, 1/1/2010. e-Pub 11/16/2009. PMCID: PMC2799235.
6. Johnson FM, Glisson BS. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nat Rev Clin Oncol 6(10):562-3, 10/2009. PMID: 19786998.
7. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. Journal of Clinical Oncology 27:3684-3690, 8/2009.
8. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol 32(3):274-9, 6/2009. e-Pub 5/2009. PMID: 19433965.
9. Holsinger FC, Kies MS, Diaz EM, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, Lee JJ, El-Naggar AK, Ki Hong W, Shin DM, Khuri FR. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 27(12):1976-82, 4/2009. e-Pub 3/2009. PMCID: PMC2738635.
10. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose Escalation of Gemcitabine Is Possible with Concurrent Chest Three-Dimensional Rather than Two-Dimensional Radiotherapy: A Phase I Trial in Patients with Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 73(1):119-127, 1/2009. e-Pub 6/2008. PMID: 18556142.
11. Saigal B, Glisson BS, Johnson FM. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anticancer Drugs 19(5):465-75, 6/2008. PMID: 18418213.
12. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. Imrt Reirradiation of Head and Neck Cancer-Disease Control and Morbidity Outcomes. Int J Radiat Oncol Biol Phys 73(2):399-409, 6/2008. e-Pub 6/2008. PMID: 18556144.
13. Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK, Morrison WH, Weber RS, Ang KK, Garden AS. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 112(12):2698-709, 6/2008. e-Pub 4/2008. PMID: 18429002.
14. William WN Jr, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol 2(8):745-50, 8/2007. PMID: 17762342.
15. Oh S-H, Lee O-H, Schroeder C, Oh Y, Ke S, Cha H-J, Park R-W, Onn A, Herbst R, Shiry L, Glisson BS, Li C, Lee H-Y. Antimetastatic Activity of IGFBP-3 In Lung Cancer is Mediated by IGF-Independent uPA Inhibition. Mol Cancer Ther 5(11):2685-95, 11/2006.
16. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 9/2006. PMID: 16943532.
17. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 3/2006. PMID: 16640804.
18. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 106(2):366-74, 1/2006. PMID: 16342249.
19. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005. PMID: 16258975.
20. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63(3):717-24, 11/2005. PMID: 16199307.
21. Sturgis EM, Moore BA, Glisson BS, Kies MS, Shin DM, Byers RM. Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series. Head Neck 27(9):748-56, 9/2005. PMID: 16086413.
22. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104(3):561-9, 8/2005. PMID: 16028213.
23. Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62(2):342-50, 6/2005. PMID: 15890573.
24. Raju U, Riesterer O, Torres M, Molkentine D, Pickett J, Koto Massashi, Matsumoto F, Johnson FM, Glisson B, Milas L, Ang KK. Mechanisms of radiation sensitization by inhibition of c-Src/c-Abl signaling. Cancer. Submitted.

Grant & Contract Support

Title: Chemo-Immunotherapy for Relapsed or Refractory Nasopharyngeal Carcinoma
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Collaborator
Principal Investigator: Dr. Chrystal Louis
Duration: 1/1/2011 - 12/31/2013
Title: M D Anderson Cancer Center Head & Neck SPORE - Project 4: Targeting EGFR and the IGF Axis for Therapy of Head and Neck Squamous Cell Carcinoma
Funding Source: NCI/NIH
Role: Project Co-Leader
Principal Investigator: Myers
Duration: 9/4/2008 - 7/31/2014

Last updated: 8/20/2013